Compare Stocks: NBRV, DERM, SLGL, and NERV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.43 +4.7%	$7.00	$4.31 ▼ $9.56	$181.46M	1.09	218,546 shs	148,360 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	N/A
NERV Minerva Neurosciences	$3.40	$4.27	$2.06 ▼ $12.46	$162.34M	-0.08	213,104 shs	62,252 shs
SLGL Sol-Gel Technologies	$69.45 +3.9%	$75.07	$27.00 ▼ $97.97	$195.15M	1.12	41,576 shs	57,954 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	0.00%	-16.01%	-17.80%	-9.57%	-13.03%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	-98.00%
NERV Minerva Neurosciences	0.00%	-7.10%	-29.75%	-37.38%	+60.38%
SLGL Sol-Gel Technologies	0.00%	+11.42%	-2.85%	-10.16%	+130.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.43 +4.7%	$7.00	$4.31 ▼ $9.56	$181.46M	1.09	218,546 shs	148,360 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	N/A
NERV Minerva Neurosciences	$3.40	$4.27	$2.06 ▼ $12.46	$162.34M	-0.08	213,104 shs	62,252 shs
SLGL Sol-Gel Technologies	$69.45 +3.9%	$75.07	$27.00 ▼ $97.97	$195.15M	1.12	41,576 shs	57,954 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	0.00%	-16.01%	-17.80%	-9.57%	-13.03%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	-98.00%
NERV Minerva Neurosciences	0.00%	-7.10%	-29.75%	-37.38%	+60.38%
SLGL Sol-Gel Technologies	0.00%	+11.42%	-2.85%	-10.16%	+130.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.25	Hold	$14.00	120.44% Upside
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A
NERV Minerva Neurosciences	1.75	Reduce	$10.33	205.27% Upside
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	183.60% Upside

Current Analyst Ratings Breakdown

Latest NBRV, DERM, SLGL, and NERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/17/2026	DERM Journey Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$61.86M	2.90	N/A	N/A	$0.96 per share	6.62
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
SLGL Sol-Gel Technologies	$19.39M	10.09	N/A	N/A	$8.19 per share	8.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$11.43M	-$0.22	N/A	7.06	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	11/19/2026 (Estimated)

Latest NBRV, DERM, SLGL, and NERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	0.64	1.59	1.41
NBRV Nabriva Therapeutics	0.12	0.85	0.52
NERV Minerva Neurosciences	N/A	20.15	20.14
SLGL Sol-Gel Technologies	N/A	10.37	10.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
NBRV Nabriva Therapeutics	0.27%
NERV Minerva Neurosciences	34.56%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	14.53%
NBRV Nabriva Therapeutics	1.63%
NERV Minerva Neurosciences	1.70%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	58	28.22 million	24.12 million	N/A
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable
SLGL Sol-Gel Technologies	28	2.81 million	941,000	No Data

NBRV, DERM, SLGL, and NERV Headlines

Recent News About These Companies

Comparing Heron Therapeutics (NASDAQ:HRTX) and Sol-Gel Technologies (NASDAQ:SLGL)

September 23, 2026 | americanbankingnews.com

SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

September 17, 2026 | zacks.com

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

September 17, 2026 | globenewswire.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys $98,448.42 in Stock

September 15, 2026 | insidertrades.com

Opaleye Management Inc. Buys 1,493 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

September 14, 2026 | marketbeat.com

Opaleye Management Inc. Acquires 1,631 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

September 14, 2026 | marketbeat.com

Sol-Gel Technologies: Phase 3 Gorlin Results Could Be The Next Major Catalyst

September 10, 2026 | rttnews.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 3,018 Shares

September 10, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 3,018 Shares

September 9, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 3,097 Shares

September 9, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 3,861 Shares

September 9, 2026 | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages

September 6, 2026 | marketbeat.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases 5,217 Shares

September 1, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 5,217 Shares of Stock

August 31, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys 35,113 Shares

August 31, 2026 | marketbeat.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | finanznachrichten.de

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | globenewswire.com

Sol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | Benzinga

July 23, 2026 | benzinga.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 Shares

July 11, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in Stock

July 3, 2026 | insidertrades.com

Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities

June 26, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV, DERM, SLGL, and NERV Company Descriptions

Journey Medical NASDAQ:DERM

$6.43 +0.29 (+4.72%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 -0.05 (-0.76%)

As of 06:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Minerva Neurosciences NASDAQ:NERV

$3.40 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.40 0.00 (-0.15%)

As of 05:11 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Sol-Gel Technologies NASDAQ:SLGL

$69.45 +2.60 (+3.89%)

Closing price 04:00 PM Eastern

Extended Trading

$69.70 +0.25 (+0.36%)

As of 05:30 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBRV, DERM, SLGL, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBRV, DERM, SLGL, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBRV, DERM, SLGL, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV, DERM, SLGL, and NERV Company Descriptions

Journey Medical NASDAQ:DERM

Nabriva Therapeutics NASDAQ:NBRV

Minerva Neurosciences NASDAQ:NERV

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBRV, DERM, SLGL, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBRV, DERM, SLGL, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBRV, DERM, SLGL, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV, DERM, SLGL, and NERV Company Descriptions

Journey Medical NASDAQ:DERM

Nabriva Therapeutics NASDAQ:NBRV

Minerva Neurosciences NASDAQ:NERV

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools